$吉利德科学(GIL_老虎社区_美港股上老虎

2020-04-28

$吉利德科学(GILD)$北卡教堂山和范德堡大学两大医学牛校的论文

免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。

精彩评论

青味
2020-04-29
青味
亏本跌出来就不轻易与这鸟啰嗦了
- czyahi:
  啥？
czyahi
2020-04-28
czyahi
就这tmd才0.13%其它股票就这论文估计都50%

发表看法

{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":925514142,"tweetId":"925514142","gmtCreate":1588071416186,"gmtModify":1704366289530,"author":{"id":3548061324702438,"idStr":"3548061324702438","authorId":3548061324702438,"authorIdStr":"3548061324702438","name":"czyahi","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":5,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p><a href=\"https://laohu8.com/S/GILD\">$吉利德科学(GILD)$</a>北卡教堂山和范德堡大学两大医学牛校的论文</p></body></html>","htmlText":"<html><head></head><body><p><a href=\"https://laohu8.com/S/GILD\">$吉利德科学(GILD)$</a>北卡教堂山和范德堡大学两大医学牛校的论文</p></body></html>","text":"$吉利德科学(GILD)$北卡教堂山和范德堡大学两大医学牛校的论文","highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":3,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/925514142","repostId":2030847402,"repostType":2,"repost":{"id":"2030847402","pubTimestamp":1588067588,"share":"https://www.laohu8.com/m/news/2030847402?lang=&edition=full","pubTime":"2020-04-28 17:53","market":"us","language":"zh","title":"吉利德发布瑞德西韦研究结果：有效抑制新冠病毒在人肺细胞中的复制","url":"https://stock-news.laohu8.com/highlight/detail?id=2030847402","media":"前瞻网","summary":"严重急性呼吸系统综合征冠状病毒2型(SARS-CoV-2)于2019年出现，成为新型大流行性病毒性疾病COVID-19的病原体。由于没有获得批准的治疗方法，本次大流行表明迫切需要针对SARS-CoV-","content":"<html><body><article><img src=\"https://fid-75186.picgzc.qpic.cn/20200428180411453v0341uu399j1su5\"/><p>严重急性呼吸系统综合征冠状病毒2型(SARS-CoV-2)于2019年出现，成为新型大流行性病毒性疾病COVID-19的病原体。</p><p>由于没有获得批准的治疗方法，本次大流行表明迫切需要针对SARS-CoV-2和未来出现的冠状病毒采取安全、广谱抗病毒对策。</p><p>近日发表在biorxiv上的一篇论文报告了remdesivir(RDV)(瑞德西韦)强有力地抑制SARS-CoV-2在人类肺细胞中和原代人气道上皮细胞培养中的复制(EC50 = 0.01 μM)。</p><img src=\"https://fid-75186.picgzc.qpic.cn/20200428180415557v034lbqt0ckh9ig\"/><p>由于其低代谢RDV的能力，在Vero E6细胞(EC50 = 1.65 μM)中观察到较弱的活动。</p><p>为了快速评估体内疗效，研究人员设计了一个嵌合的SARS-CoV，编码SARS-CoV-2病毒的RDV(依赖RNA的RNA聚合酶)靶点。</p><p>在嵌合病毒感染的小鼠中，与经载药处理的动物相比，治疗性RDV减少了肺病毒载量，改善了肺功能。</p><p>研究人员表示，这些数据为RDV在体内外对SARS-CoV-2具有强大的活性提供了大量证据，为进一步的COVID-19治疗的临床试验提供了支持。</p><p>该研究作者隶属于Gilead Sciences, Inc.，是公司的雇员，拥有公司的股份。其他作者没有利益冲突的报告。</p><p>Gilead(吉利德公司)生产瑞德西韦，这种药被认为是治疗新冠肺炎的有希望的药物。不过，日前有消息称瑞德西韦在中国的一项临床试验中失败了，而吉利德当时对此发布声明称，预期在本月底发布针对瑞德西韦用于新型冠状病毒肺炎重症患者的开放标签研究的结果。</p><p>编译/前瞻经济学人APP资讯组</p><p>原文来源：</p><p>https://www.biorxiv.org/content/10.1101/2020.04.27.064279v1</p></article></body></html>","source":"tencent","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>吉利德发布瑞德西韦研究结果：有效抑制新冠病毒在人肺细胞中的复制</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n吉利德发布瑞德西韦研究结果：有效抑制新冠病毒在人肺细胞中的复制\n</h2>\n\n<h4 class=\"meta\">\n\n\n2020-04-28 17:53 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202004281804167afea2d9&s=b><strong>前瞻网</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>严重急性呼吸系统综合征冠状病毒2型(SARS-CoV-2)于2019年出现，成为新型大流行性病毒性疾病COVID-19的病原体。由于没有获得批准的治疗方法，本次大流行表明迫切需要针对SARS-CoV-2和未来出现的冠状病毒采取安全、广谱抗病毒对策。近日发表在biorxiv上的一篇论文报告了remdesivir(RDV)(瑞德西韦)强有力地抑制SARS-CoV-2在人类肺细胞中和原代人气道上皮细胞...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202004281804167afea2d9&s=b\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://static.tigerbbs.com/6ad7ed6b96b448ffcc5b5501b0dc346c","relate_stocks":{"GILD":"吉利德科学"},"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202004281804167afea2d9&s=b","is_english":false,"share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","article_id":"2030847402","content_text":"严重急性呼吸系统综合征冠状病毒2型(SARS-CoV-2)于2019年出现，成为新型大流行性病毒性疾病COVID-19的病原体。由于没有获得批准的治疗方法，本次大流行表明迫切需要针对SARS-CoV-2和未来出现的冠状病毒采取安全、广谱抗病毒对策。近日发表在biorxiv上的一篇论文报告了remdesivir(RDV)(瑞德西韦)强有力地抑制SARS-CoV-2在人类肺细胞中和原代人气道上皮细胞培养中的复制(EC50 = 0.01 μM)。由于其低代谢RDV的能力，在Vero E6细胞(EC50 = 1.65 μM)中观察到较弱的活动。为了快速评估体内疗效，研究人员设计了一个嵌合的SARS-CoV，编码SARS-CoV-2病毒的RDV(依赖RNA的RNA聚合酶)靶点。在嵌合病毒感染的小鼠中，与经载药处理的动物相比，治疗性RDV减少了肺病毒载量，改善了肺功能。研究人员表示，这些数据为RDV在体内外对SARS-CoV-2具有强大的活性提供了大量证据，为进一步的COVID-19治疗的临床试验提供了支持。该研究作者隶属于Gilead Sciences, Inc.，是公司的雇员，拥有公司的股份。其他作者没有利益冲突的报告。Gilead(吉利德公司)生产瑞德西韦，这种药被认为是治疗新冠肺炎的有希望的药物。不过，日前有消息称瑞德西韦在中国的一项临床试验中失败了，而吉利德当时对此发布声明称，预期在本月底发布针对瑞德西韦用于新型冠状病毒肺炎重症患者的开放标签研究的结果。编译/前瞻经济学人APP资讯组原文来源：https://www.biorxiv.org/content/10.1101/2020.04.27.064279v1","news_type":1},"isVote":1,"tweetType":1,"viewCount":3254,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":["GILD"],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":58,"xxTargetLangEnum":"ZH_CN"},"commentList":[{"id":2391128,"commentId":"2391128","gmtCreate":1588143246949,"gmtModify":1588143246949,"authorId":3506555657566519,"author":{"id":3506555657566519,"idStr":"3506555657566519","authorId":3506555657566519,"name":"青味","avatar":"https://static.tigerbbs.com/7468c2029b03fb5afb50a00b42e6dcec","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":925514142,"objectIdStr":"925514142","type":1,"supId":0,"supIdStr":"0","prevId":0,"prevIdStr":"0","content":"亏本跌出来就不轻易与这鸟啰嗦了","text":"亏本跌出来就不轻易与这鸟啰嗦了","html":"亏本跌出来就不轻易与这鸟啰嗦了","likeSize":0,"commentSize":1,"subComments":[{"id":2391133,"commentId":"2391133","gmtCreate":1588143296391,"gmtModify":1588143296391,"authorId":3548061324702438,"author":{"id":3548061324702438,"idStr":"3548061324702438","authorId":3548061324702438,"name":"czyahi","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":925514142,"objectIdStr":"925514142","type":1,"supId":2391128,"supIdStr":"2391128","prevId":0,"prevIdStr":"0","content":"啥？","text":"啥？","html":"啥？"}],"verified":10,"allocateAmount":0,"commentType":"valid","coins":0,"score":0},{"id":2387633,"commentId":"2387633","gmtCreate":1588071450769,"gmtModify":1588071846836,"authorId":3548061324702438,"author":{"id":3548061324702438,"idStr":"3548061324702438","authorId":3548061324702438,"name":"czyahi","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":925514142,"objectIdStr":"925514142","type":1,"supId":0,"supIdStr":"0","prevId":0,"prevIdStr":"0","content":"就这tmd才0.13%其它股票就这论文估计都50%","text":"就这tmd才0.13%其它股票就这论文估计都50%","html":"就这tmd才0.13%其它股票就这论文估计都50%","likeSize":0,"commentSize":0,"subComments":[],"verified":10,"allocateAmount":0,"commentType":"valid","coins":0,"score":0}],"isCommentEnd":false,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/925514142"}